Abstract
Introduction
Glioblastoma is the most common and malignant brain tumour and current treatment modalities include surgical resection, adjuvant radiotherapy and temozolomide chemotherapy [1] . The goal of cancer therapies is either to inhibit cell growth or to activate cell death pathways [2] . [3, 4] [5, 6] . Further studies, however, have shown that the majority of glioblastomas are resistant to TRAIL-induced apoptosis [7] . Here, we report the molecular mechanisms that control TRAIL resistance in the tumours.
Several cell death pathways have been identified, including apoptosis, autophagy, mitotic catastrophe and necrosis. Glioblastoma is diffusely invasive and the invasive tumour cells become resistant to the treatments because of the activation of cell growth and/or inhibition of cell death pathways

. Tumour necrosis factor-related apoptosis-inducing ligand (TRAIL) has recently emerged as a cancer therapeutic agent because of its capability of inducing apoptosis in glioblastoma cells
TRAIL is expressed in natural killer cells and lymphocytes [8] as a type II membrane protein, with a short intracellular N-terminal tail and a long extracellular C-terminal [9] . The C-terminal has the receptor-binding site and can generate a soluble biologically active recombinant human TRAIL (rhTRAIL) [10] . Although clinical development of rhTRAIL as a therapeutic agent was stalled when polyhistidine-tagged rhTRAIL was reported to be hepatotoxic [11] , the subsequent studies have shown that non-tagged rhTRAIL is not toxic to human hepatocytes in vitro [12] and in vivo [13] . [15] in the lipid rafts of the plasma membrane [16] . The homotrimeric formation of death receptors [17] is required for the receptor-mediated assembly of the DISC [18] . Unlike death receptors, decoy receptors have the cysteine-rich domains but lack the functional cytoplasmic DD, so they inhibit TRAIL-induced apoptosis [19, 20] by interrupting the homotrimeric formation of death receptors [17, 21] .
Recently, a phase I clinical trial has confirmed that the non-tagged
DR5-mediated DISC controls caspase-8 cleavage and initiation of apoptosis in human glioblastomas
Caspase-8 cleavage in the DISC is the upstream event in TRAIL-induced apoptosis. Caspase-8 is synthesized as a zymogen and exists in two isoforms (p55 and p53), each consisting of two death effector domains (DEDs) and a protease domain of p18
and p10 subunits [22] . Through the DED, caspase-8 zymogens are recruited by FADD to the DISC and cleaved through two-step autoproteolytic processes for the release of p18 and p10 subunits [23, 24] [9] . The DISC can be modified by intracellular adaptors, leading to the inhibition of caspase-8 and activation of cell survival pathways [25] . Through the DD, [26] . [27] and phosphoprotein enriched in diabetes or in astrocyte-15 (PED/PEA-15) [28] and thus couples the DISC to NF-B and extracellular signal-regulated kinases 1/2 (ERK1/2) pathway [29, 30] .
that initiate apoptotic cascade by cleavage of caspase-3 and Bcl-2 inhibitory BH3-domain protein (Bid) and subsequent activation of mitochondrial pathway
DR4 and DR5 can recruit a DD adaptor, tumour necrosis factor receptor 1 (TNFR1)-associated death domain (TRADD), which in turn recruits receptor-interacting protein (RIP) and inhibitor of B (I-B) kinases (IKK) to the DISC, leading to IKK activation, I-B phosphorylation and nuclear factor-B (NF-B) activation
Through the DED, FADD recruits intracellular DED adaptors, cellular FADD-like interleukin-1␤-converting enzyme inhibitory protein (c-FLIP)
These 
Reducing and non-reducing SDS and Western blots
In vivo trapping of active caspases
This assay was carried out based on a previous report [32] . 
Electrophoretic mobility shift assay (EMSA)
Nuclear extracts were prepared from the cells according to the method described in a previous report [33] . 
Lipid raft and non-raft fractionation and cholesterol analysis
Lipid raft and non-raft fractions were separated by discontinuous sucrose density gradients of Triton-X 100 cell lysates [34] . (Fig. 1C) . DR4 was detected only in 1 of the 10 tumours but not in any of the normal brain tissues (Fig. 1C) (Fig. 1C) .
Results
DcR1 and DcR2 are not expressed in human glioblastomas
To [35] . In this study, we further examined RIP and c-FLIP expression. Relatively consistent levels of RIP were detected in all the cell lines (Fig. 1C) (Fig. 2A) . Although DR4 protein was detected in LN18 and LN443 cells (Fig. 1C) , Western blot analysis of the immunoprecipitants from these two cell lines detected no DR4 (Fig. 2B) (Fig. 2C) . DR4 protein was detected in LN18 cells in the reducing and nonreducing gel, but the non-reducing gel failed to show DR4 homotrimer (Fig. 2D) . Finally, we transfected LN18 cells with DR4 and DR5 siRNA to knock down the receptors (Fig. 2E) and showed that the knockdown of DR5 but not DR4 significantly inhibited TRAIL-induced cell death (Fig. 2F) . These results clearly demonstrate that DR5, but not DR4, is the functional TRAIL receptor. (Fig. 3A) . In contrast, the cleavage of caspase-8 and caspase-3 was inhibited in LN443 cells regardless of the presence or absence of bVAD-fmk (Fig. 3A) .
1C). DcR1 was not detected in any of the normal brain and tumour tissues, whereas DcR2 was seen in 3 of 10 tumours (Fig. 1C). Flow cytometry detected neither DcR1 nor DcR2 in any of the cell lines (data not shown). The failure to detect DcR1 and DcR2 in glioblatoma cell lines and tumour tissues has therefore ruled out the role of the decoy receptors in TRAIL resistance. DD and DED adaptors, RIP, c-FLIP and PED/PEA-15 may play a role in TRAIL resistance. PED has been reported to be highly expressed in human glioblastomas
Caspase-8 cleavage is inhibited in TRAIL resistance
Next (Fig. 3B) ; the result indicates that caspase-8 is the initiator protease of downstream caspases in TRAIL-induced apoptosis. In contrast, however, no [26] . Interestingly, RIP was expressed at consistent levels in sensitive and 1310 
Fig. 2 DR5 is the TRAIL functional receptor. Glioblastoma cell lines, as indicated above the panel, were immunoprecipitated by Flag-TRAIL/M2 antibody before (ϩ) and after (-) the cells were lysed and subjected to Western blotting with DR5 (A) and DR4 antibody (B). Cell extract (EX) was included as a control of the endogenous proteins. Glioblastoma cell lines were treated (ϩ) or untreated (-) with 300 ng/ml TRAIL for 30 min. and examined by Western blots under reducing and non-reducing conditions for the presence of the homotrimeric complex of DR5 (C) and DR4 (D). * indicates a non-specific band. (E) TRAIL-sensitive LN18 cells were transfected with scramble, DR4 and DR5 siRNA for 72 hrs and examined by Western blot for the expression of DR4 and DR5, with ERK1/2 used as a loading control. (F). LN18 cells were transfected with scramble, DR4 and DR5 siRNA or double-transfected with DR4 and DR5 siRNA cells, treated with 300 ng/ml TRAIL and examined for cell death by the cell viability assay (mean Ϯ S.E.M., n ϭ 4).
Fig. 3 bVAD-fmk trapping of activated initiator caspase-8. (A) TRAIL-sensitive U343MG cells and TRAIL-resistant LN443 cells were pre-treated with bVAD-fmk for 2 hrs and stimulated with 300 ng/ml TRAIL for the times indicated above the panel. The cells were lysed and subjected to Western blotting for cleavage of caspase-8 (Casp-8) and caspase-3 (Casp-3). (B) U343MG and LN443 cells were treated with bVAD-fmk and then TRAILand bVAD-fmk-trapped activated caspases were pulled down by streptavidin and examined by Western blotting, with acetyl-CoA carboxylase as a control for precipitation and loading. cleavage product of either caspase-8 or caspase-3 was seen in LN443 cells (Fig. 3B), which indicates that the initiator caspase-8-initiated caspase cascade is inhibited in TRAIL resistance.
Caspase-8 is recruited but not cleaved in TRAIL resistance
To investigate the molecular mechanisms involved in the inhibition of caspase-8 cleavage, we compared the DISC components of TRAIL-sensitive U343MG cells with those of TRAIL-resistant LN443 cells. For the DISC analysis, the cells were treated with mixed Flag-tagged TRAIL and Flag antibody for 15 min. and immunoprecipitated with protein G-sepharose [15]. For the unstimulated control, the cells were lysed first, treated with mixed Flag-TRAIL/M2 antibody and subjected to immunoprecipitation. The immunoprecipitants were examined on Western blots and DR5, FADD and caspase-8 were detected in the DISC in both U343MG and LN443 cells (Fig. 4A). Western blots detected the caspase-8 zymogens (p55/53), the first-step cleavage products (p43/41) in the DISC of the sensitive U343MG cells (Fig. 4A). In contrast, the caspase-8 zymogens but not the cleavage products were detected in the DISC of LN443 cells; the result indicates that the zymogens are recruited to the DISC but fail to be cleaved in the DISC in the resistant cells. Next, we examined the DISC-depleted supernatants and found the caspase-8 p18 subunit in the supernatants from the sensitive U343MG but not the resistant LN443 cells (Fig. 4B), which indicates the release of the caspase-8 protease subunits from the DISC to the cytosol, in which they cleave downstream caspase-3 in TRAIL-induced apoptosis. The DISC analysis further detected RIP, c-FLIP (both c-FLIPL and c-FLIPS) and PED/PEA-15 in the DISC in the resistant LN443 but not the sensitive U343MG cells (Fig. 4A). TRADD was not detected in the DISC in any of the cell lines, regardless of the earlier report that RIP is recruited to the DISC through TRADD in the transfectant
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Fig. 4 The DISC modification leads to the inhibition of caspase-8 cleavage. (A) TRAIL-induced DISC was immunoprecipitated by treating LN443 (left panel) and U343MG (right panel) cells with Flag-TRAIL/M2 antibody for 15 min. (ϩ). For the unstimulated control, the cells were lysed first and then incubated with Flag-TRAIL/M2 antibody for 15 min. (-). Cell lysates (EX) were included as controls. The samples were examined by Western blotting for the presence of the proteins indicated on the left panel, with molecular weights on the right panel. (B) The supernatants collected from LN443 and U343MG cells after the DISC depleted, as described above in (A), were examined by Western blots for caspase-8 cleavage products, with the molecular weights indicated on the right side of the panel. (C) Western blot of the DISC analysis with RIP antibody (right third blot in (A)) was overexposed to show RIP in the unstimulated control (-) and the DISC (ϩ) of U343MG cells. (D) LN443 and U343MG cells were treated with 300 ng/ml TRAIL in the absence or presence of caspase-8 inhibitor z-IETD for 6 hrs and subjected to Western blotting for the expression of RIP (p74) and its cleavage product (p43).
resistant cell lines (Fig. 1C) but only detected in the DISC of the resistant line (Fig. 4A) . To examine this further, we first overexposed the Western blots and showed weak bands of RIP in the DISC in the sensitive U343MG cells (Fig. 4C) , which suggests that RIP might be associated with DR5 but is cleaved off the DISC, perhaps by the activated caspase-8 in the DISC (Fig. 4A) . (Fig. 4D ). (Fig. 5A) , consistent with an earlier report [37] . TRAIL treatment increased slightly the NF-B activity in the resistant LN443 but not the sensitive U343MG cells (Fig. 5A) (Fig. 5B) . To determine the role of DR5 in TRAIL-induced NF-B activity, LN443 cells were transfected with DR5 siRNA and the luciferase reporter assays showed that transfection of DR5 siRNA eliminated TRAILinduced NF-B activity (Fig. 5C) [38] .
To test this, we treated U343MG and LN443 cells with TRAIL and showed that TRAIL treatment resulted in the RIP cleavage from the full length (74 kD) to the cleavage (43 kD) product in U343MG but not LN443 cells and the presence of caspase-8 inhibitor z-IETD-fmk eliminated the RIP cleavage in the sensitive U343MG cells
NF-B activity has no effect on TRAIL resistance
The detection of RIP in the DISC in resistant cells suggests the possibility that RIP may mediate TRAIL-induced NF-B signalling in the cells. To test this, U343MG and LN443 cells were treated with TRAIL and examined first by EMSA for NF-B DNA-binding activity. Both cell lines showed a low constitutive NF-B activity
. To further explore the role of NF-B, a panel of two TRAIL-sensitive (LN71 and LN18) and four TRAIL-resistant cell lines were examined for NF-B transcriptional activity by an NF-B-responsive luciferase reporter assay. The results showed that TRAIL treatment increased the NF-B activity in all the resistant but not the sensitive lines
; the results indicate that DR5 is required for TRAIL-induced NF-B activity. To further examine the role of TRAIL-induced NF-B activity in TRAIL resistance, TRAIL-resistant LN443 cells were treated with parthenolide, an inhibitor of the I-B phosphorylation
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Fig. 5 TRAIL-induced NF-B activity does not contribute to TRAIL resistance. (A) U343MG and LN443 cells were untreated (-) or treated (ϩ) with 300 ng/ml TRAIL for 30 min. and examined for NF-B DNA-binding activity by EMSA. (B) TRAIL-sensitive (LN71 and LN18) and TRAIL-resistant cell lines (U118MG, U138MG, U87MG and LN443) were treated with 300 ng/ml TRAIL for 6 hrs and examined by an NF-B-responsive luciferase reporter assay. (C) LN443 cell were transfected with either scramble or DR5 siRNA for 72 hrs, treated with 300 ng/ml TRAIL for 6 hrs and examined by the luciferase reporter assay. (D) LN443 cells were treated or untreated with 10 M parthenolide for 16 hrs and followed with 300 ng/ml TRAIL treatment for the hours as indicated before being subjected to Western blot analysis of the expression of phosphorylated I-B (p-I-B), total I-B, c-FLIP, PED/PEA-15 and RIP, with actin as a loading control. TRAIL-resistant LN443 and U138MG cells were treated with 10 M parthenolide for 16 hrs and then with 300 ng/ml TRAIL for 3 hrs for the luciferase reporter assay (E) and for 24 hrs for the cell death assay (F).
Parthenolide treatment eliminated the TRAIL-induced phosphorylation of I-B in LN443 (Fig. 5D) (Fig. 5D) . We then treated TRAIL-resistant LN443 and U138MG cells first with parthenolide and then with TRAIL for the luciferase reporter and cell viability assays; the results showed that the parthenolide treatment eliminated TRAIL-induced NF-B activity (Fig. 5E) ; however, the inhibition of NF-B activity by parthenolide had no effect on the cell resistance to TRAIL (Fig. 5F ). Taken together, these studies establish the role of DR5 in TRAIL-induced activation of NF-B; however, TRAIL-induced NF-B activity does not contribute to TRAIL resistance in glioblastoma cells. (Fig. 6B) . The cell viability assay further showed a significant cell death in the TRAIL-treated cells transfected with siRNA specific to RIP, c-FLIP and PED/PEA-15 as compared with scramble siRNA (Fig. 6C) .
but did not affect the protein expression of c-FLIP, PED/PEA-15 and RIP in the cells
RIP, c-FLIP and PED/PEA-15 contribute to TRAIL resistance
Transfection of c-FLIP siRNA did not alter the expression of caspase-8 (Fig. 6B) , a homologue of c-FLIP [27] ; the results indicate the specific knockdown of c-FLIP by the siRNA. The knockdown of RIP had no effect on the expression of c-FLIP, ruling out the possibility that RIP-mediated NF-B activity may up-regulate c-FLIP in TRAIL resistance, as reported in TNF pathway [39] (Fig. 7A) . Lipid rafts are rich in cholesterol and the examination of cholesterol showed a higher content of cholesterol in fractions 4 and 5 of lipid rafts (Fig. 7B) . Western blots further detected DR5 but not caspase-8 and FADD in lipid raft fractions (Fig. 7C) ; however, treatment with TRAIL led to the redistribution of caspase-8 and FADD to lipid rafts (Fig. 7D) 
Discussion
Our earlier work has characterized human glioblastoma cell lines into TRAIL-sensitive and -resistant phenotypes [5] . TRAIL-induced apoptosis has been well documented in the sensitive cells, in which TRAIL binds on the cell surface death receptors for the recruitment of FADD and caspase-8 [15] , the autoproteolytic cleavage of caspase-8 and the initiation of apoptosis by cleavage of downstream caspase-3 and Bid [6] . These studies have provided the basis for clinical development of rhTRAIL as a glioblastoma therapeutic agent. These studies have also shown the resistance of the majority of glioblastoma cells to TRAIL treatment [5] [6] [7] . In the investigation of the molecular mechanisms, we have shown that TRAIL resistance occurs in the DISC in TRAIL-resistant glioblastoma cells.
TRAIL signalling begins by binding of its receptors on the cell surface [9] . DR4 [40] and fibrosarcoma HT1080 [41] express DR5, whereas chronic lymphocytic leukaemia undergoes apoptosis through DR4 [42] . Second, each of the receptors may induce different intracellular signals. DR5 may contribute to TRAIL-induced apoptosis [43] , whereas DR4 may mediate TRAILinduced NF-B signals [44] . In this study, we have shown that DR5 but not DR4 is the functional receptor that is abundantly expressed on the cell surface (Fig. 1), forms homotrimer (Fig. 2) and mediates the DISC assembly (Fig. 4) for TRAIL-induced apoptotic (Fig. 3) and NF-B signals (Fig. 5) [19] [20] [21] . The transcripts of DcR1/2 were detected in some human cancer cells, thus raising the concern on the usefulness of rhTRAIL as a therapeutic agent [14] . To explore the role of endogenous DcR1/2, we have shown that DcR1/2 proteins are not expressed in glioblastoma cell lines and tumour tissues (Fig. 1) . This study rules out the potential role of endogenous DcR1/2 in TRAIL resistance in glioblastomas.
TRAIL resistance may result from the DISC modifications by intracellular DD and DED adaptors [25] . Studies of transfectants have shown that DR5 interacts with TRADD and through TRADD it recruits RIP to the DISC [26] for the NF-B activation [45] . Through the DED-DED interaction, FADD recruits c-FLIP and PED/PEA-15 to the DISC, where caspase-8 cleavage is inhibited [15] . While these molecular models have been well documented in transfectants, our studies have established several unique features of the DISC modifications in TRAIL-resistant glioblastoma cells (Fig. 4) (Fig. 6) .
RIP can recruit IKK complex to the DISC for the phosphorylation and degradation of I-B and activation of NF-B [26, 46] . NF-B signalling may induce the expression of c-FLIP, thereby inhibiting TRAIL-induced apoptosis [39] signalling promotes tumour migration and metastasis [47] . In this study, we have shown that the DISC is the bifurcation site in which RIP inhibits caspase-8 cleavage (Fig. 4) and couples to NF-B pathway (Fig. 5) . Our studies, however, have further clarified that it is the inhibition of caspase-8 in the DISC (Fig. 4) but not the NF-B activity that inhibits TRAIL-induced apoptosis in glioblastoma cells (Fig. 5) . This study suggests that targeting of NF-B pathways is able to eliminate TRAIL resistance in glioblastoma cells. [48] and DR5-induced apoptosis [16] . In contrast, however, lipid rafts have been reported for TNFR1-initiated activation of NF-B and ERK1/2 [49, 50] . In examining the role of lipid rafts, we have shown that lipid rafts are required for the DISC assembly in TRAIL-induced apoptosis in the sensitive glioblastoma cells (Fig. 7) ; however, the lipid raft model fails to explain the DISC assembly in TRAILinduced NF-B signalling in the resistant cells. In search of the molecular mechanisms, we have shown that the non-raft phase of the plasma membrane mediates TRAIL-induced DISC assembly in the resistant cells, thereby contributing to the TRAIL resistance (Fig. 8) 
DR5-mediated DISC is a membrane-associated complex and lipid rafts have been implicated in Fas-
